What does the Pluvicto (lutetium Lu 177 vipivotide tetraxetan) label say it’s for?
Pluvicto is an FDA-approved radiopharmaceutical indicated for adults with:
- Metastatic castration-resistant prostate cancer (mCRPC) that is prostate-specific membrane antigen (PSMA)-positive, and
- Have been treated with an androgen receptor pathway inhibitor (ARPI) and a taxane-based chemotherapy (if medically appropriate) [1].
Who can get Pluvicto under the FDA label?
The labeled population is adults with PSMA-positive metastatic mCRPC as described above, after prior ARPI and taxane treatment (when appropriate for the patient’s medical situation) [1].
What dosing and administration details are typically in the Pluvicto label?
The FDA label describes Pluvicto as a radiopharmaceutical administered by healthcare professionals, with specific instructions for:
- Patient preparation and imaging/PSMA selection approach needed to confirm PSMA-positive disease, and
- Dose administration and radiation safety precautions appropriate for a therapeutic radiopharmaceutical [1].
What are the biggest label safety warnings patients ask about?
The Pluvicto label includes important safety information, including boxed or prominent warnings/sections covering potential serious risks associated with treatment, along with monitoring guidance during therapy [1].
What common reasons doctors decide against using Pluvicto (based on labeling constraints)?
Prescribers typically consider whether the patient meets labeled criteria (PSMA-positive status and prior therapies) and whether expected risks outweigh potential benefit, using the label’s safety and patient-selection requirements [1].
Where can I read the official Pluvicto label?
You can review the current prescribing information (FDA label) here: [1].
Source
[1] https://www.drugs.com/label/pluvicto.html